DIHYDROPYRANOCOUMARINS FROM ROOTS OF PEUCEDANUM JAPONICUM

YASUMASA IKESHIRO, IZUMI MASE and YUTAKA TOMITA

Department of Pharmacognosy and Phytochemistry, Niigata College of Pharmacy, 5-13-2 Kamishinei-cho, Niigata 950-21, Japan

(Received in revised form 7 April 1992)

Key Word Index—Peucedanum japonicum; Umbelliferae; roots; dihydropyranocoumarins; peujaponisin;(-)-visnadin; ¹³C NMR.

Abstract—Two new angular-type dihydropyranocoumarins, peujaponisin and (-)-visnadin, were isolated from the roots of *Pencedanum japonicum* and the structures determined as 3'(S)-senecioyloxy-4'(S)-isovaleryloxy-3',4'-dihydroseselin and 3'(S)-2-methylbutyryloxy-4'(S)-acetoxy-3',4'-dihydroseselin, respectively, by spectroscopic analysis and chemical reactions.

INTRODUCTION

The dried roots (Shoku-Bohfuu in Japanese) of Peucedanum japonicum (Umbelliferae), are used for coughs, colds, heachaches and as an antifebrile and anodyne in Japan. In our previous study [1], we isolated a mixture of acetylangeloyloxy-3',4'-dihydroseselin and acetyltigloyloxy-3',4'-dihydroseselin from roots of this plant. From the roots, three dihydropyranocoumarins were subsequently isolated, 3'(S), 4'(S)-diisovaleryloxy-3', 4'dihydroseselin (1), 3'(S), 4'(S)-disenecioyloxy-3', 4'dihydroseselin (2) [2] and (+)-samidin (3) [3]. Recently, three angular-type dihydropyranocoumarin derivatives have been isolated from this crude drug and identified as antihistaminic, calcium-blocking and cytotoxic natural products [4, 5]. The constituents of roots of P. japonicum were studied and two new angular-type dihydropyranocoumarins, peujaponisin (4) and (-)-visnadin (5), were isolated along with four known dihydropyranocoumarins, 1-3 and (+)-anomalin (6) [1, 6, 7]. This study was conducted in order to isolate these related compounds and to determine their structures.

RESULTS AND DISCUSSION

Compound 4 was found to have the molecular formula, C_{24} H₂₈ O₇ ([M]⁺ m/z 428.1593). Its UV spectrum with maxima at 216 (sh), 245 (sh), 255, 297 (sh) and 323 nm, indicated it to possess a 7-oxycoumarin moiety and its IR spectrum showed absorption for a carbonyl group (1730 cm⁻¹) and an aromatic ring (1605 cm⁻¹), both characteristic of the coumarin skeleton. The ¹H NMR spectrum showed three AB quartet systems at $\delta 6.24$, 7.60 (each 1H, d, J = 9.5 Hz, H-3, H-4), $\delta 7.36$, 6.79 (each 1H, d, J = 8.6 Hz, H-5, H-6) and $\delta 5.32$, 6.58 (each 1H, d, J = 5.0 Hz, H-3', H-4'), and gem-dimethyl groups at $\delta 1.42$, 1.46 (each 3H, s). The complex signals at $\delta 1.89$, 2.23 (each 3H, d, J = 1.3 Hz) and $\delta 5.63$ (1H, m) were due to a senecicyl group, while those at $\delta 0.94$ -2.24 were ascribed to an *iso*valeryl moiety.

Alkaline hydrolysis of 4 gave (-)-cis-khellactone (7) and (+)-trans-khellactone (8) as artifacts from epimeriz-



- 5 R¹=COCH(Me)CH₂Me R²=COMe
- 6 R¹=R²=COC(Me)=CHMe
- 7 $R^1 = R^2 = H$
- 9 R¹=H
- 11 R¹=COCH=C(Me)₂
 - $R^2 = C_2 H_5$

ation at the benzylic 4'-position, along with senecioic and isovaleric acids. Ethanolic alkaline hydrolysis of 4 gave (-)-cis (9) and (+)-trans-ethylkhellactone (10). By partial hydrolysis with 1 N ethanolic NaOH [8, 9], 4 gave the khellactone ester as a viscous oil (11), subsequently identified as 3'(S)-senscioyloxy-4'(S)-ethoxy-3',4'-dihydroseselin, based on a comparison (TLC, IR, ¹H NMR, ¹³C NMR and mass spectra) with an authentic sample prepared from 3. The isovaleryl group of 4 is thus linked to the 4'-hydroxyl group of 7. It thus follows that the structure of 4 is 3'(S)-senecioyloxy-4'(S)-isovaleryloxy-3',4'-dihydroseselin. Compound 5 had the molecular formula, C_{21} H₂₄ O₇ ([M]⁺ m/z 388). Its ¹H NMR and mass spectra were quite similar to those of peucedanocoumarin I (12) [10]. Chemical shifts of the ¹³C NMR signals of 5 were in good agreement with those of 12, except for those arising due to its gem-dimethyl groups (Table 1). By alkaline hydrolysis, 5 gave 7 and 8 along with 2-methylbutyric acid and acetic acid. Based on the present results, 5 may be considered to have the structure, 3'(S)-2-methylbutyryloxy-4'(S)acetoxy-3',4'-dihydroseselin, which is the C-3' and C-4' enantiomer of visnadin [11, 12].

For compound 6, IR, UV and ¹H NMR spectra were virtually the same as those of (+)-anomalin [1, 7]. By alkaline hydrolysis, 6 gave 7 and 8, with angelic acid, and was identified by a comparison with authentic (+)-anomalin isolated from *P. formosanum* [1].

EXPERIMENTAL

Mps: uncorr. EIMS:20 and 70 eV, HRMS:70 eV. ¹H and ¹³C NMR:200, 400 MHz and 50, 100 MHz, respectively, with TMS as an int. std. CC: Mallinckrodt silica gel (100 mesh). TLC and prep. TLC:silica gel 60 GF₂₅₄ plates (0.25 mm) and silica gel 60 PF₂₅₄ plates (0.5 mm). Spots and bands were detected by UV irradiation (254 and 365 nm).

Plant material. Dried roots of Peucedanum japonicum Thumb. were cultivated and collected in the botanical garden of this college in September 1987. The crude drug (Shoku-Bohfuu) was supplied by Uchida Wakan-Yaku Company, Ltd. Ogatacho, Niigata.

Extraction and isolation. Finely cut roots (1.5 kg) were extracted with MeOH (31×3) at room temp. for 2 hr. The comb. MeOH extracts were concd in vacuo. The residue (490 g) was dissolved in H₂O and extracted successively with n-hexane (200 ml \times 3), Et₂O (200 ml \times 3), EtOAc (200 ml \times 3), and *n*-BuOH (210 ml \times 5). An aliquot (63 g) of the *n*-hexane extract (144 g) was subjected to CC on silica gel (900 g) and eluted successively with a n-hexane-EtOAc (100:1) mixt. of increasing polarity. A total of 70 frs were collected. Frs 29-38 were repeatedly subjected to prep. TLC (silica gel, n-hexane EtOAc, 5:1) to yield the six crude coumarins. Each was further purified by recrystallisation and prep. TLC (n-hexane-EtOAc 5:1; 10 developments), yielding in order of increasing polarity: 1 (1.1 g), (+)-anomalin (6) (1.15 g), 4 (1.23 g), 5(13 mg), 2 (75 mg) and (+)-samidin (3) (450 mg). Known coumarin compounds were identified by comparison of their spectroscopic properties with lit. values.

Peujaponisin (4). Oily $[\alpha]_{25}^{25} - 7.0^{\circ}$, $[\alpha]_{578}^{25} - 9.0^{\circ}$, $[\alpha]_{346}^{25} - 13.0^{\circ}$, $[\alpha]_{436}^{25} - 83.0^{\circ}$, $[\alpha]_{255}^{25} - 603.0^{\circ}$ (CHCl₃; c 1.0). UV $\lambda_{max}^{\text{meoH}}$ nm (log e): 216 (sh. 4.56), 245 (sh. 4.00), 255 (3.88), 297 (sh. 4.06), 323 (4.23); IR $\nu_{max}^{\text{CHCl}_3}$ cm⁻¹: 1730, 1650, 1605, 1465; ¹H NMR (400 MHz, CDCl₃): see Table 2. ¹³C NMR (100 MHz, CDCl₃): see Table 1. EIMS 70 eV, m/z (rel. int.): 428 [M]⁺ (1), 326 (6), 311 (11), 261 (13), 244 (17), 229 (44), 213 (9), 85 (37), 83 (100). HRMS m/z: 428.1593 ([M]⁺, calcd. for C₂₄H₂₈O₇ : 428.1621), 326.1125 (C₁₉H₁₈O₅: 326.1152), 311.0951 (C₁₈H₁₅O₅: 311.0918).

(-)-Visnadin (5). Oily, $[\alpha]^{22} - 12.9^{\circ}$, $[\alpha]^{24}_{546} - 16.2^{\circ}$, $[\alpha]^{24}_{436} - 45.2^{\circ}$, $[\alpha]^{22}_{555} - 241.9^{\circ}$ (CHCl₃; c 0.31). UV λ_{max}^{MeOH} nm (log e): 218 (sh. 4.17), 244 (sh. 3.74), 255 (3.66), 297 (sh. 3.96), 323 (4.10). IR v^{CHCl3} cm⁻¹: 1720, 1605, 1520, 1485, 1455. ¹H NMR

с	1	2	3	4*	5*	6
2	159.6 s	159.8 s	159.8 s	159.8 s	159.7 s	159.7 s
3	113.3 d	113.2 d	113.3 d	113.2 d	113.3 d	113.3 d
4	143.2 d	143.2 d	143.1 d	143.1 d	143.3 d	143.1 d
5	129.3 d	129.0 d	129.2 d	129.1 d	129.4 d	129.2 d
6	114.4 d	114.4 d	114.4 d	114.4 d	114.5 d	114.4 d
7	156.6 s	156.8 s	156.7 s	156.7 s	156.6 s	156.8 s
8	107.5 s	107.6 s	107.5 s	107.6 s	107.4 s	107.6 s
4a	112.5 s	112.5 s	112.6 s	112.5 s	112.5 s	112.5 s
8a	154.1 s	154.1 s	154.1 s	154.1 s	154.0 s	154.2 s
2'	77.3 s	77.3 s	77.4 s	77.5 s	77.2 s	77.5 s
3'	70.5 d	69.5 d	70.8 d	70.4 d	70.8 d	70.3 d
4'	60.5 d	59.8 d	59.6 d	59.6 d	60.3 d	60.2 d
gem-Me	22.5 q	22.6 q	22.2 q	22.5 q	21.8 q	22.5 q
	25.4 q	25.1 q	25.4 q	25.3 q	25.6 q	25.4 g
3'-Ester				-	-	-
1	171.8 s	165.2 s	165.2 s	165.1 s	175.6 s	166.3 s
2	43.3 t	115.3 d	115.1 d	115.2 d	41.4 d	127.1 s
3	25.4 d	158.1 s	158.0 s	157.9 s	26.6 t	139.7 d
4	22.5 q	27.4 q	27.4 q	27.4 q	11.6 q	15.5 g
5	22.5 q	20.3 q	20.4 q	20.4 q	16.6 q	20.4 q
4'-Ester		-	-	-	-	•
1	171.7 s	165.1 s	169.9 s	171.8 s	169.7 s	166.5 s
2	43.1 t	115.4 d	20.7 q	43.1 t	20.7 q	127.5 s
3	25.6 d	157.4 s		25.4 d	•	138.3 d
4	22.5 q	27.4 q		22.4 q		15.7 a
5	22.2 q	20.3 q		22.4 q		20.3 q

Table 1. ¹³C NMR spectral data of compounds 1-6 in CDCl₃

*Assignments confirmed by¹H-¹³C COSY experiments.

SFORD and DEPT multiplicity.

805

н	4	5	
3	6.24 d	6.20 d	
	(9.5)	(9.5)	
4	7.60 d	7.60 d	
	(9.5)	(9.5)	
5	7.36 d	7.38 d	
	(8.6)	(8.6)	
5	6.79 d	6.78 d	
	(8.6)	(8.6)	
3′	5.32 d	5.28 d	
	(5.0)	(5.0)	
ť	6.58 d	6.48 d	
	(5.0)	(5.0)	
<i>jem-</i> Me	1.46 s	1.45 s	
	1.42 s	1.42 s	
3'-Ester			
2	5.63 m	2.41 m	
		1.72 m	
		1.45 m	
ļ.	2.23 d	0.94 t	
	(1.3)	(7.5)	
;	1.89 d	1.21 d	
	(1.3)	(7.0)	
'-Ester		. ,	
2	2.24 m	2.09 s	
3	2.11 m	_	
	0.97 d	_	
ł			
ł	(6.6)		
;	(6.6) 0.95 d	_	

Table 2. ¹HNMR spectral data of

All assignments were confirmed by ${}^{1}H-{}^{1}H 2D COSY.$

Values in parentheses are coupling constants in Hz.

(200 MHz, $CDCl_3$):see Table 2. ¹³C NMR (50 MHz, $CDCl_3$):see Table 1. EIMS 70 eV, m/z (rel. int.):388 [M]⁺ (5), 328 (5), 313 (10), 244 (32), 229 (100), 85 (70), 57 (38).

(+)-Anomalin (6). Needles, mp $173-174^{\circ}$. $[\alpha]_D^{23}+38.2^{\circ}$ (CHCl₃; c 2.76). IR, UV and ¹H NMR spectra essentially identical with those reported [1, 7, 9]. ¹³CNMR (50 MHz, CDCl₃): see Table 1. EIMS 70 eV, m/z (rel. int.):426 [M]⁺ (2), 327 (24), 326 (11), 311 (15), 244 (6), 229 (33), 227 (7), 213 (4), 83 (100), 55 (69).

Alkaline hydrolysis of peujaponisin (4). Compound 4 (600 mg) was treated with 5% NaOH (60 ml), and the reaction mixt. refluxed for 2 hr. The reaction mixt. was acidified with dil.H₂SO₄, extracted with Et₂O, washed with 10% NaHCO₃ soln, dried with Na₂SO₄ and evapd; the residue was subjected to CC (silica gel, n-hexane-EtOAc, 2:1) to yield two products. The first eluant gave (-)-cis-khellactone (7) as needles (85 mg), mp $173-174^{\circ}$. $[\alpha]_{D}^{27}-75.7^{\circ}$ (CHCl₃; c 0.33). ¹³C NMR: see Table 3. EIMS 70 eV, m/z (rel. int.): 262 [M]⁺ (22), 192 (12), 191 (100), 162 (35), 134 (27), 107 (14). The second eluant gave (+)-transkhellactone (8) as needles (105 mg), mp 185–186°. $[\alpha]_{D}^{25} + 19.8^{\circ}$ (CHCl₃; c 0.50). ¹³C NMR (50.10 MHz, CDCl₃):see Table 3. EIMS 70 eV, m/z (rel. int.): 262 [M] + (11), 192 (13), 191 (100), 190 (12), 162 (25), 134 (29), 107 (12). These substances 7 and 8 were identified by comparison with respective authentic samples (mmp, IR and ¹H NMR). The acidic portion was converted to the *p*-phenylphenacyl ester in the usual way. The crude product was subjected to prep. TLC (C_6H_6) and recrystallized from EtOH to afford *p*-phenylphenacyl isovalerate as lustrous platelets, mp 78.5-79° [11, 13], and *p*-phenylphenacyl senecioate, lustrous platelets, mp 145-146° [1, 11, 14]. These esters were identical to the respective authentic samples (mmp, MS and ¹H NMR).

Ethanolic alkaline hydrolysis of peujaponisin (4). Compound 4 (300 mg) dissolved in EtOH (10 ml) was added to 1 N ethanolic NaOH (20 ml), and the reaction mixt. refluxed for 1 hr. After work-up in the usual way, the reaction product was subjected to CC on silica gel eluting with *n*-hexane-EtOAc (1:1) to give (-)-*cis-ethylkhellactone* (9) as needles (15.4 mg), mp 126-127°. $[\alpha]_D^{23}$ - 77.04° (CHCl₃; *c* 1.35). ¹H NMR (200 MHz, CDCl₃): $\delta 6.24$ (1H, *d*, J = 9.5 Hz, H-3), 7.62 (1H, *d*, J = 9.5 Hz, H-4), 7.30 (1H, *d*, J = 8.6 Hz, H-5), 6.74 (1H, *d*, J = 8.6 Hz, H-6), 3.84 (1H, *d*, J = 5.0 Hz, H-3'), 4.82 (1H, *d*, J = 5.0 Hz, H-4'), 1.40, 1.46 (each 3H, *s*, *gem*-Me₂), 3.98 (2H, *qm*, J = 8.0 Hz, -CH₂Me), 1.34 (3H, *t*, J = 8.0 Hz, -CH₂Me). ¹³C NMR (50 MHz, CDCl₃):see Table 3. EIMS 70 eV, *m/z* (rel. int.): 290 [M]⁺ (13), 219 (34), 218 (60), 191 (51), 190 (32), 162 (62), 149 (12), 134 (36), 107 (10), 77 (19), 57 (22), 43 (100).

(+)-trans-Ethylkhellactone (10). Needles (113 mg), mp 157-158°. $[\alpha]_{L^5}^{25} + 84.5°$ (CHCl₃; c 0.64). ¹H NMR (200 MHz, CDCl₃): $\delta 6.18$ (1H, d, J = 9.5 Hz, H-3), 7.56 (1H, d, J = 9.5 Hz, H-4), 7.26 (1H, d, J = 8.6 Hz, H-5), 6.74 (1H, d, J = 8.6 Hz, H-6), 3.88 (1H, d, J = 3.0 Hz, H-3'), 4.63 (1H, d, J = 3.0 Hz. H-4'), 1.48, 1.44 (each 3H, s, gem-Me₂), 4.06 (2H, qm, J = 8.0 Hz, -CH₂Me), 1.28 (3H, t, J = 8.0 Hz, -CH₂Me). ¹³C NMR (50 MHz, CDCl₃):see Table 3. EIMS 70 eV, m/z (rel. int.): 290 [M]⁺ (23), 219 (49), 218 (84), 191 (95), 190 (50), 189 (16), 176 (15), 175 (14), 162 (100), 149 (12), 134 (61), 107 (14), 77 (19), 59 (26), 43 (83), identified by direct comparison with authentic samples (mmp, IR and ¹H NMR). The acid portion was worked-up as described above to afford pphenylphenacyl senecioate and p-phenylphenacyl isovalerate.

Partial hydrolysis of peujaponisin (4). Compound 4 (300 mg) was treated with 1 N ethanolic NaOH (20 ml) and the mixt. stirred at room temp. for 10 min. After working up in the usual way, the reaction product was subjected to prep. TLC (silica gel) with n-hexane-EtOAc (5:1) to give viscous oil (11) (120 mg), $[\alpha]_{D}^{23} - 94.2^{\circ} \text{ CHCl}_{3}; c 1.08$). ¹H NMR (200 MHz, CDCl₃): $\delta 6.22$ (1H, d, J = 9.5 Hz, H-3), 7.58 (1H, d, J = 9.5 Hz, H-4), 7.30 (1H, d, J = 8.6 Hz, H-5), 6.77 (1H, d, J = 8.6 Hz, H-6), 4.54 (1H, d, J = 2.5 Hz, H-3'), 5.18 (1H, d, J = 2.5 Hz, H-4'), 1.49, 1.42 (each 3H, s, gem-Me₂), 5.60 (1H, q, J = 1.3 Hz, $-CH = C(Me)_2$), 2.14, 1.84 (each 3H, d, J = 1.3 Hz, $2 \times Me$), 4.04 (2H, q, J = 8.0 Hz, $-CH_2Me$), 1.30 (3H, t, J = 8.0 Hz, $-CH_2Me$). ¹³C NMR (50 MHz. CDCl₃):see Table 3. EIMS 70 eV, m/z (rel. int.):372 [M]⁺ (2), 327 (18), 257 (30), 229 (20), 83 (100), 55 (15). The acid portion was worked-up as described above to afford p-phenvlphenacyl isovalerate. Identification with 3'-(S)-senecioyloxy-4' (S)-ethoxy-3',4'-dihydroseselin from 3 by the same reaction as above was established by comparison of MS, $[\alpha]_D$, ¹H NMR and ¹³CNMR spectra.

Alkaline hydrolysis of (-)-visnadin (5). Compound 5 (12 mg) was treated with 5% NaOH (10 ml) and the reaction mixt. refluxed for 2 hr. Working up as described above yielded a product, which was subjected to prep. TLC (*n*-hexane-EtOAc, 2:1, 4 developments) to yield 7 (2.6 mg) and 8 (3.8 mg). The acid portion was worked-up as described above to afford *p*-phenylphenacyl acetate, lustrous platelets, mp 110–111° [1] and *p*-phenylphenacyl 2-methylbutyrate, lustrous platelets, mp 68–70° [11]. These substances were identical to the respective authentic samples by ¹H NMR comparison.

Alkaline hydrolysis of (+)-anomalin (6). Compound 6 (350 mg) was treated in the same manner as described for 4 to give 7

<u>c</u>	7	8	9	10	11
2	161.2 s	161.5 s	160.7 s	160.9 s	160.8 s
3	112.1 d	112.0 d	112.6 d	112.8 d	112.4 d
4	144.3 d	144.4 d	143.8 d	143.6 d	143.6 d
5	128.6 d	128.4 d	128.8 d	128.5 d	128.5 d
6	114.9 d	114.8 d	114.6 d	114.6 d	114.6 d
7	156.6 s	156.4 s	156.8 s	156.3 s	156.2 s
8	111.1 s	111.8 s	109.7 s	109.3 s	108.6 s
4a	112.2 s	112.5 s	112.4 s	112.6 s	112.8 s
8a	154.6 s	154.3 s	154.8 s	155.1 s	155.0 s
2'	79.1 s	79.5 s	78.8 s	78.4 s	79.7 s
3'	71.2 d	74.8 d	70.3 d	72.7 d	69.9 d
4′	61.1 d	66.4 d	69.6 d	71.4 d	69.5 d
gem-Me	21.6 q	20.3 q	22.2 q	23.7 q	23.6 a
	25.3 q	25.4 q	25.1 g	24.2 q	25.4 a
3'-Ester	-	•			
1			10100		165.3 s
2				And a second	115.3 d
3			and a second		158.9 s
4	_				27.4 a
5					20.4 a
4'-OC ₂ H ₅			68.5 t	68.8 t	66.4 t
			15.8 a	15.8 a	15.6 a

Table 3. ¹³C NMR spectral data of compounds 7-11 in CDCl₃

Assignment by selective decoupling.

SFORD and DEPT multiplicity.

(45 mg), 8(56 mg) and *p*-phenylphenacyl angelate, lustrous platelets, mp $87-88^{\circ}$ [9]. These substances were identified by comparison with the respective authentic samples.

Acknowledgement—We thank Dr A. Kato (Niigata College of Pharmacy), for the measurements of HR and EI mass spectra.

REFERENCES

- 1. Hata, K., Kozawa, M., Ikeshiro, Y. and Yen, K. Y. (1968) Yakugaku Zasshi 88, 513.
- Yamada, Y., Hsu, C. S., Iguchi, K. and Suzuki, M. (1974) Tetrahedron Letters 29, 2513.
- 3. Shigematsu, N., Kouno, I. and Kawano, N. (1982) Yakugaku Zasshi 102, 392.
- 4. Duh, C. Y., Wang, S. K. and Wu, Y. C. (1991) *Phytochemistry* 30, 2812.

- Takeuchi, N., Kasama, T., Aida, Y., Maruyama, I., Watanabe, K. and Tobinaga, S. (1991) Chem. Pharm. Bull. 39, 1415.
- 6. Okuyama, T. and Shibata, S. (1981) Planta Med. 42, 89.
- 7. Kohda, H. and Satake, M. (1982) Shoyakugaku Zasshi 36, 88.
- 8. Hata, K., Kozawa, M. and Ikeshiro, Y. (1966) Chem. Pharm. Bull. 14, 94.
- 9. Hata, K., Kozawa, M. and Ikeshiro, Y. (1967) Yakugaku Zasshi 87, 1118.
- Takata, M., Shibata, S. and Okuyama, T. (1990) Planta Med. 56, 307.
- Smith, E., Hosansky, N., Bywater, W. G. and van Tamelen, E. E. (1957) J. Am. Chem. Soc. 79, 3534.
- 12. Lemmich, J., Pedersen, P. A. and Nielsen, B. E. (1969) Tetrahedron Letters 39, 3365.
- 13. Willete, R. E. and Soine, T. O. (1962) J. Pharm. Sci. 51, 149.
- 14. Nielsen, B. E. and Soine, T. O. (1967) J. Pharm. Sci. 56, 184.